Navigation Links
Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Date:9/5/2011

AMSTERDAM, September 6, 2011 /PRNewswire/ --


Gains US Patent Protection for Proprietary AAV Intellectual Property

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications. This agreement expands on an original non-exclusive license for AAV5 from the NIH. Financial details of the agreement have not been disclosed.

Concurrent with the signing of this exclusive license, AMT has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "AAV vectors produced in insect cells", which covers a core asset of the Company's proprietary manufacturing technology. This patent comprises a novel and significantly improved method of delivery of therapeutic genes to targets using adeno-associated viral (AAV) derived vectors produced in insect cells. The technology has already been successfully applied to Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD). AMT believes this intellectual property together with the NIH exclusive license places the Company in a unique position for a number of AAV serotype 5-based programs, including hemophilia, acute intermittent prophyria, GDNF-related diseases and Sanfilippo B.

"This expansion of our existing AAV5 license with NIH is an important addition to our intellectual property position as it supports several of our pipeline products that follow Glybera. The granting of an exclusive license by the NIH is very unusual and we believe acknowledges AMT's status in the gene therapy sector," stated Jörn Aldag, CEO of AMT. "As well as continuing to work diligently towards the re-examination of Glybera registration dossier, we also appreciate the significant valu
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Molecular sleuths track evolution through the ribosome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... Guide, ,I. Description ,II. Product Components ... ,IV. Protocol for Extraction of DNA from Whole Blood ... Whole Blood ,VI. Quantification of Amplified Products ... Application Data , References , Contact Information ...
... ,I. Description ,II. Product Components ,III. ... Protocol for Extraction of DNA from Blood Card ... Card ,VI. Quantification of Amplified Products ,VII. ... , References , Contact Information , , ,Application ...
... , , ... , , , Mutations ... of the colon, pancreas, liver, spleen, stomach or lungs. The,CDKN2A/P16 gene is ... which point mutation is present,in patient tissue samples. Freshly frozen tumor sections ...
Cached Biology Technology:Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 2Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 3Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 4Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 5Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 6Protocol for GenomePlex Whole Genome Amplification from Blood Card 2Protocol for GenomePlex Whole Genome Amplification from Blood Card 3Protocol for GenomePlex Whole Genome Amplification from Blood Card 4Protocol for GenomePlex Whole Genome Amplification from Blood Card 5Protocol for GenomePlex Whole Genome Amplification from Blood Card 6Mutation detection for the,K- rasand P16 genes 2Mutation detection for the,K- rasand P16 genes 3Mutation detection for the,K- rasand P16 genes 4Mutation detection for the,K- rasand P16 genes 5Mutation detection for the,K- rasand P16 genes 6
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... A tiny wasp that lays its eggs under the ... most diverse groups of insects on Earth. Now researchers ... thought. (To see an audio slide show on ... By combining ecological and genetic data with the painstaking ...
... risk during cardiac procedures. Doctors performing heart surgery also ... IAEA is helping to raise awareness of threats, through ... X-ray imaging systems. The issue of radiation protection ... of lengthy angioplasty and other cardiac interventions performed under ...
... insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts ... treatment, said researchers at Baylor College of Medicine in a ... Journal of Clinical Oncology. The finding gives impetus to ... various tumors. "These findings come at a critical time," ...
Cached Biology News:Diversity among parasitic wasps is even greater than suspected 2Diversity among parasitic wasps is even greater than suspected 3Protecting those who heal 2Growth factor predicts poor outcome in breast cancer 2
6B9...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Biology Products: